The short version of melanocortin fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Early clinical work used an intranasal formulation, and later programmes switched to subcutaneous delivery for more consistent absorption. A subcutaneous product received regulatory approval in the United States in 2019 for premenopausal women with acquired, generalised hypoactive sexual desire disorder. Approval followed phase 3 trials in which active treatment separated from placebo on desire and distress measures, though the average difference was modest. Labeling carries a caution about transient blood pressure elevation, so cardiovascular history is assessed before prescribing. Questions about durability of benefit beyond several months remain open.
Published discussion sits at the intersection of peptide chemistry, neuroendocrinology and sexual medicine. Trial reports emphasise change scores on validated instruments, while mechanistic papers focus on hypothalamic circuits and receptor selectivity. Because placebo response in this field is large, effect sizes are usually reported with confidence intervals rather than as isolated averages. Reviews note that female and male data sets are not interchangeable and should be read separately. Diagnostic terminology has been revised over time, which complicates comparison between older and newer studies.
Bremelanotide is a synthetic cyclic heptapeptide that acts on a family of G-protein-coupled receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide associated with pigmentation and several central signalling pathways. A lactam bridge constrains the ring and slows enzymatic breakdown, which distinguishes it from the linear parent molecule. Research interest moved over time from pigment biology toward central nervous system effects, particularly circuits connected to sexual desire. Parenteral delivery is used because oral bioavailability is poor.
Bremelanotide functions as an agonist at several melanocortin receptor subtypes, with the strongest functional activity reported at the MC4 subtype. MC4 receptors sit in hypothalamic circuits that influence appetite, energy balance, and components of sexual behaviour. Rodents lacking functional MC4 receptors show altered mating behaviour, which supports a role for this pathway in desire. The precise sequence of events connecting receptor activation to reported human effects remains only partly characterised. Because the same receptor family governs pigmentation and inflammatory signalling, selectivity is a recurring theme in pharmacological discussion.
Clinical programmes in this area have relied mainly on randomised, double-blind, placebo-controlled designs in premenopausal women. Primary endpoints usually combine a validated questionnaire covering desire domains with counts of satisfying sexual events and a separate measure of distress. Reported outcomes show statistically significant but modest average improvement over placebo, with wide individual variation. Adverse events such as nausea, flushing, and headache occur frequently and can limit tolerability. Whether short-term trial gains translate into lasting change for most users is an open question.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analogue of alpha-MSH |
| Molecular mass | Approximately 1025 Da | Peptide-scale molecule |
| Route | Subcutaneous injection | Intranasal form used in early research |
| Common synonyms | PT-141; bremelanotide acetate | Research code and salt form |
| Typical storage | 2-8 °C, protected from light | Unopened vial condition |
PT-141 initiates cellular signaling by binding to specific subtypes within the melanocortin receptor family. These receptors belong to the G protein-coupled receptor superfamily, and activation raises intracellular cyclic adenosine monophosphate levels. This cascade ultimately influences neuronal circuits in the central nervous system that are associated with sexual desire and arousal. Research indicates the compound's action concentrates in hypothalamic regions rather than peripheral tissues, which helps explain some observed pharmacological features. The selectivity of receptor binding underlies its functional differences.
Compared with the related compound melanotan II, PT-141 shows markedly weaker activation of receptors tied to pigmentation. This difference stems from subtle structural variations that alter affinity distribution across receptor subtypes. Investigators propose that such selectivity produces a different side effect profile in specific applications. However, downstream consequences of prolonged receptor activation remain uncertain in the literature. Published studies do not fully agree on the duration of signaling pathway activity and the mechanisms of desensitization.
From a pharmacokinetic standpoint, the peptide is usually delivered by injection because oral bioavailability is very low; proteases in the digestive tract degrade it rapidly. After subcutaneous administration, plasma concentrations reach a peak within roughly one hour. Its elimination half-life is relatively short, with most reports placing it in the range of a few hours. Nasal formulations have also been examined, though absorption varies widely between individuals. Metabolism proceeds mainly through peptidase cleavage, and the resulting products are excreted by the kidneys.
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
Routine characterisation of bremelanotide relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nm, where the peptide backbone absorbs. Mass spectrometry, typically in tandem mode with electrospray ionisation, confirms identity and supports quantification in biological matrices. Additional checks include amino acid analysis, peptide mapping after enzymatic digestion, and confirmation of the lactam bridge, since incomplete cyclisation produces a mass-shifted by-product. Purity values above 95 percent are common in reference-grade material, though reports vary in how strictly related substances are resolved from the parent peak.
The lyophilised solid is relatively stable when kept dry, protected from light and held at reduced temperature, commonly minus 20 degrees Celsius or lower for long-term storage. In solution the peptide is more vulnerable: tryptophan oxidation, hydrolysis of the lactam bridge and aggregation all become relevant over time, and the rate depends on pH, buffer composition and concentration. Repeated freeze-thaw cycles are generally avoided because they promote aggregation. Aqueous working solutions are typically prepared fresh or split into single-use aliquots to limit degradation before analysis.
Published studies differ in design, population and endpoint definition, so results are not always directly comparable across reports. Some trials used patient-reported measures of desire and distress, while others tracked physiological or behavioural outcomes. Questions that remain open include the durability of effects beyond short follow-up periods, the frequency of transient blood pressure elevation observed after administration, and whether a subtype-selective analogue could separate central effects from pigmentation-related activity. These points are usually framed as unresolved rather than settled in review literature.
Lyophilised peptide is generally held below minus twenty degrees Celsius, protected from light and moisture, because hydrolysis and oxidation accumulate faster at ambient temperature. Once reconstituted, solutions are typically kept between two and eight degrees Celsius and used within a short window defined by the supplier. Repeated freeze-thaw cycles are avoided since they promote aggregation and loss of soluble material. Container material matters as well, because peptides adsorb to certain plastics and glass surfaces at low concentration. Stability figures supplied by a vendor apply only to the specific lot and buffer that were tested.
Identity and purity are usually established with reversed-phase high-performance liquid chromatography combined with mass spectrometry. A gradient of water and acetonitrile containing trifluoroacetic acid is a common mobile phase, and ultraviolet detection near 214 nanometres responds to the peptide backbone. Mass spectrometry confirms the expected molecular mass and helps reveal truncation or oxidation products. Purity is reported as a peak-area percentage, a figure that depends on the wavelength and gradient used, so values from different laboratories are not always directly comparable. Peptide mapping and amino acid analysis provide additional confirmation when required.
Regulatory status varies by jurisdiction, where approved prescription products, compounded preparations and research-grade material are treated as distinct categories with different documentation requirements. Suppliers of research material commonly issue a certificate of analysis listing purity, identity and sometimes endotoxin content. Independent verification by a third-party laboratory is often recommended because self-reported figures are difficult to check. Literature discussions usually state the source, purity and storage conditions of the material used, since these details affect reproducibility. Analysts note that a reported purity figure does not by itself describe biological activity.
==== Static vs. dynamic freezing profiles ==== If a freeze casting setup with a constant temperature on either side of the freezing system is used, (static freeze-casting) the front solidification velocity in the SSZ will decrease over time due to the increasing thermal buffer caused by the growing ice front. When this occurs, more time is given for the anisotropic ice crystals to grow perpendicularly to the freezing direction (c-axis) resulting in a structure with ice lamellae that increase in thickness along the length of the sample.
=== Glass fiber filters === Glass fiber filter has the pore size of 1 μm, it is useful for filtering highly contaminated solutions or difficult-to-filter solution. Also, glass fiber filter has extends filter life, wide range of particulate loads and can prevent sample contamination. In addition, different types of glass fiber filter are suitable for different filtration situation. There are 7 different types of glass fiber filters and the major difference is thickness.
=== Development === T3 has profound effect upon the developing embryo and infants. It affects the lungs and influences the postnatal growth of the central nervous system. It stimulates the production of myelin, the production of neurotransmitters, and the growth of axons. It is also important in the linear growth of bones.
Sources: en.wikipedia.org
=== Business units === Sea Solutions – Operates under the brands 2GO Freight and 2GO Travel. 2GO Freight provides door-to-door and pier-to-pier transportation of raw materials and finished goods via full container load (FCL), less-than-container load (LCL), and loose cargo shipments, using a fleet of roll-on/roll-off (RoRo) passenger-cargo vessels (RoPax). 2GO Travel offers passenger sea transportation nationwide, providing affordable travel with hotel, tour, and event packages. Logistics – Provides land, air, and sea transportation, warehousing, cross-docking, trucking, cold chain solutions, ISO tank and liquid bulk transport, domestic and international freight forwarding, customs brokerage, project logistics, and last-mile and e-commerce delivery. Distribution – Operates under ScanAsia Overseas Inc. (SOI), providing nationwide product distribution to retail outlets. SOI originally focused on dairy products and later expanded to fast-moving consumer goods (FMCG) and pharmaceuticals. The Board approved the cessation of Scanasia Overseas, Inc. operations effective 31 March 2024.
=== May === May 15, 2009: France, Austria, Belgium, Romania, Lithuania, Luxembourg, Portugal, Hungary The French Institute of Statistics and Economic Studies announced that French gross domestic product shrank 1.2% in the first quarter of 2009 after falling by 1.5% in the final quarter of 2008. The French economy had avoided narrowly a recession in 2008. The GDP is expected to keep shrinking in 2009. Eurostat also reported at this time that Austria, Belgium, and Romania had all entered recession in the first quarter of 2009, with two consecutive quarters of shrinking GDP, while Lithuania, Luxembourg, and Portugal had already done so in the last quarter of 2008 and Hungary in the quarter before that.
== ECU Health-owned hospitals == ECU Health Medical Center, Greenville - Flagship Hospital ECU Health Beaufort Hospital, Washington ECU Health North Hospital, Roanoke Rapids ECU Health Bertie Hospital, Windsor ECU Health Chowan Hospital, Edenton ECU Health Duplin Hospital, Kenansville ECU Health Edgecombe Hospital, Tarboro ECU Health Roanoke-Chowan Hospital, Ahoskie The Outer Banks Hospital, Nags Head (jointly owned with Chesapeake Regional Healthcare) Former facilities:
Sources: en.wikipedia.org
=== Mass spectrometry === Paper-spray ionization is being rapidly developed as an interface for micro paper-based analytical devices μPAD and mass spectrometry. The technique, first described by Graham Cooks group at Purdue, involves applying a voltage to a triangular sheet of wet paper near the inlet of a mass spectrometer. Although the exact mechanism is not well understood, two modes of operation can occur: a multicone spray at high flow rates, and a single cone spray that occurs when solvent has been depleted. This is part of a larger effort to combine complex microfluidic manipulations with mass spectral detection. Wax printing hydrophobic barriers is a common method for creating distinct flow channels within paper devices, and this has been extended to μPAD-MS to enhance ionization efficiency (by enabling focusing of the analyte stream) and enable reaction mixing by wax printing on the triangular paper surface. Chromatographic separations have also been demonstrated on μPADs prior to paper-spray detection. Initially, paper-spray ionization was applied for the detection of small molecules, such as pharmaceuticals and drugs of abuse. However, it has also been shown that paper-spray ionization can ionize large proteins while retaining non-covalent interactions.
diphosphate + uridylyl-[protein-PII] Thus, the two substrates of this enzyme are UTP and protein-PII, whereas its two products are diphosphate and uridylyl-[protein-PII]. This enzyme belongs to the family of transferases, specifically those transferring phosphorus-containing nucleotide groups (nucleotidyltransferases). The systematic name of this enzyme class is UTP:[protein-PII] uridylyltransferase. Other names in common use include PII uridylyl-transferase, and uridyl removing enzyme. This enzyme participates in two-component system - general.
== Production and isolation == The lightest isotopes (244Md to 247Md) are mostly produced through bombardment of bismuth targets with argon ions, while slightly heavier ones (248Md to 253Md) are produced by bombarding plutonium and americium targets with ions of carbon and nitrogen. The most important and most stable isotopes are in the range from 254Md to 258Md and are produced through bombardment of einsteinium with alpha particles: einsteinium-253, −254, and −255 can all be used. 259Md is produced as a daughter of 259No, and 260Md can be produced in a transfer reaction between einsteinium-254 and oxygen-18. Typically, the most commonly used isotope 256Md is produced by bombarding either einsteinium-253 or −254 with alpha particles: einsteinium-254 is preferred when available because it has a longer half-life and therefore can be used as a target for longer. Using available microgram quantities of einsteinium, femtogram quantities of mendelevium-256 may be produced. The recoil momentum of the produced mendelevium-256 atoms is used to bring them physically far away from the einsteinium target from which they are produced, bringing them onto a thin foil of metal (usually beryllium, aluminium, platinum, or gold) just behind the target in a vacuum. This eliminates the need for immediate chemical separation, which is both costly and prevents reusing of the expensive einsteinium target. The mendelevium atoms are then trapped in a gas atmosphere (frequently helium), and a gas jet from a small opening in the reaction chamber carries the mendelevium along.
Roseanne Park. Musician/Performer. For services to the United Kingdom COP 26 Presidency and advocacy for the 2021 United Nations Climate Change Conference of the Parties. Gina Cecile Petrie. Director, Department of Environment, Cayman Islands. For services to the Environment and to the community in the Cayman Islands. Richard Anthony Power. Orthopaedic Surgeon, University Hospitals of Leicester NHS Trust; Chair, Health Action Leicester in Ethiopia. For services to Health in Gondar, Northern Ethiopia. Natalie Ray Pray. Former President, the St George's Society, New York, United States of America. For services to UK/US Cultural Relations and to Philanthropy. Phillip Christopher Robinson. Team Leader, Foreign, Commonwealth and Development Office. For services to National Security. James Andrew Rogers. Head of Coordination, Windsor Framework Taskforce, Foreign, Commonwealth and Development Office. For services to British Foreign Policy. Lynette Silver. Historian and Author. For services to British Families of World War II personnel. Claire Sonia van Straubenzee. Founder and Trustee, The Henry van Straubenzee Memorial Fund. For services to Children's Education in Uganda. Edward Robert Syfret. Angola Programme Manager, the HALO Trust. For services to Humanitarian Demining in Angola. Margery Anne Taylor. District Treasurer and District Training Officer, Royal British Legion, Spain South. For services to Veterans in Spain. Jacqueline Barbara Teasdale (Tig James). Co-President, British in Portugal. For services to the British Community in Portugal. John Robert Thurlow.
Sources: en.wikipedia.org
It is a synthetic cyclic peptide that activates melanocortin receptors. It is given by injection and was approved in the United States in 2019 for a specific low-desire diagnosis in premenopausal women. It is not a hormonal therapy.
Earlier approaches were largely hormonal or psychological in focus, whereas this compound acts on central melanocortin signalling. It is not a vasodilator and does not share the mechanism of phosphodiesterase inhibitors. Head-to-head comparative data are limited.
Placebo responses in desire trials are large, so the average drug-placebo separation is small. Reporting therefore relies on validated questionnaires with statistical ranges. Individual responses vary widely.
The approved formulation is given by subcutaneous injection and is used on an as-needed basis rather than on a fixed daily schedule. An intranasal version was studied earlier but did not reach the same stage of development. Route of delivery strongly affects how quickly the peptide appears in circulation.